Phenidate drug formulations having diminished abuse potential
US6355656B1 · kind B1 · utility
105Cited by
16References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 25, 1999 |
| Grant date | Mar 12, 2002 |
| Priority date | — |
| Expiry date | May 25, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12P41/006
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Phenidate drug formulations are provided having reduced potential for drug abuse. Dosage forms for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS are provided which minimize drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential. Such dosage forms comprise D-threo stereoisomer of a phenidate in the substantial absence of all other stereoisomers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.